Aurora, a Global Leader in Medical Cannabis, Announces Results of 2026 Annual General Meeting
Rhea-AI Summary
Aurora Cannabis (NASDAQ: ACB; TSX: ACB) reported voting results from its 2026 Annual General Meeting held virtually on August 7, 2026. Shareholders representing 16,639,306 common shares, or 26.86% of shares outstanding, were present or represented by proxy.
All five board nominees—Miguel Martin, Michael Singer, Chitwant Kohli, Norma Beauchamp and Rajesh Uttamchandani—received between roughly 85% and 87% of votes cast in favour. Shareholders also approved the reappointment of Ernst & Young LLP as auditors for the coming year and passed the advisory say‑on‑pay resolution with 82.97% of votes FOR.
Positive
- 16,639,306 shares represented, equal to 26.86% of outstanding shares at record date
- All five director nominees received between 85.12% and 86.52% of votes FOR
- Advisory say-on-pay resolution approved with 82.97% of votes FOR
- Ernst & Young LLP appointed as auditors for the ensuing year
Negative
- None.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Aug 05 | quarterly results | Negative | +3.6% | Revenue fell and adjusted EBITDA declined despite a narrower net loss. |
| Jul 27 | proxy support | Positive | +2.6% | ISS recommended FOR all AGM resolutions ahead of shareholder voting. |
| Jul 23 | EU-GMP certification | Positive | +1.1% | Safari Flower Company received three-year EU-GMP certification for its Niagara facility. |
| Jul 22 | conference call | Neutral | +1.1% | Company scheduled a call to discuss first-quarter 2027 financial results. |
| Jul 09 | company recognition | Positive | +0.4% | Aurora received recognition on TIME Canada's Best Companies 2026 list. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Three positive announcements aligned with positive reactions; mixed quarterly results and a neutral call-scheduling notice also recorded positive reactions, creating two divergences.
Key Terms
say-on-pay financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
The details of the voting results for the directors are set out below:
Board Nominee | Votes For | % votes For | Votes Withheld | % Votes Withheld |
Miguel Martin | 5,076,096 | 85.12 % | 887,633 | 14.88 % |
Michael Singer | 5,148,795 | 86.34 % | 814,934 | 13.66 % |
Chitwant Kohli | 5,134,736 | 86.10 % | 828,993 | 13.90 % |
Norma Beauchamp | 5,159,834 | 86.52 % | 803,895 | 13.48 % |
Rajesh Uttamchandani | 5,127,871 | 85.98 % | 835,857 | 14.02 % |
At the Meeting, shareholders also approved the appointment of Ernst & Young LLP as auditors of the Company for the ensuing year, and approved the Company's advisory vote on executive compensation, otherwise known as "Say-on-Pay", which passed with
"We're pleased by the support received from our shareholders at this year's meeting," said Miguel Martin, Executive Chairman and CEO at Aurora. "These results demonstrate confidence in our Board of Directors and allow us to remain focused on executing our medical-first strategy, strengthening our global medical cannabis business, and delivering long-term value for shareholders."
A report of voting results on all resolutions voted on at the Meeting will be filed under the Company's profile on SEDAR + (www.sedarplus.ca).
About Aurora
Aurora is a global leader in medical cannabis, dedicated to improving lives through scientific expertise, proven performance, and a deep commitment to patient care. Aurora serves medical markets across Canada, Europe, Australia, and New Zealand with a portfolio of trusted, leading brands including Aurora®, MedReleaf®, Pedanios®, IndiMed™, San Raf®, and Whistler Medical Marijuana Corporation®. With world-class GMP-certified manufacturing facilities in Canada and Germany, and a team of industry-leading professionals, Aurora continues to expand its global footprint and deliver consistent, high-quality cannabis products with the purpose of Opening the World to Cannabis™.
Learn more at www.auroramj.com and follow us on X and LinkedIn.
Aurora's common shares trade on the NASDAQ and TSX under the symbol "ACB".
Forward Looking Information
This news release includes statements containing certain "forward-looking information" within the meaning of applicable securities law ("forward-looking statements"). Forward-looking statements are frequently characterized by words such as "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed" and other similar words, or statements that certain events or conditions "may" or "will" occur. Forward-looking statements made in this news release include, but are not limited to, statements regarding the execution of the Company's medical-first strategy, strengthening of its global business, and the Company's ability to deliver long-term value for shareholders.
Forward-looking information or statements contained in this news release have been developed based on the Company and its management's good faith assumptions relating to the financial, market, regulatory and other relevant environments that will exist and affect the Company's business and operations in the future. Forward-looking information and statements are not a guarantee of future performance and are based upon a number of estimates and assumptions of management at the date the statements are made including, among other things, assumptions about: development costs remaining consistent with budgets; the ability to manage anticipated and unanticipated costs; access to favorable equity and debt capital markets; the ability to raise sufficient capital to advance the business of the Company; favorable operating and economic conditions; political and regulatory stability; obtaining and maintaining all required licenses and permits; receipt of governmental approvals and permits; sustained labour stability; stability in financial and capital goods markets; favorable production levels and costs from the Company's operations; the pricing of various cannabis products; the level of demand for cannabis products; the availability of third-party service providers and other inputs for the Company's operations; and the Company's ability to conduct operations in a safe, efficient, and effective manner. The Company does not give any assurance that the assumptions on which forward-looking information or statements are based will prove to be correct, or that the Company's business or operations will not be affected in any material manner by these or other factors not foreseen or foreseeable by the Company or management or beyond the Company's control. Such forward-looking statements are estimates reflecting the Company's best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that other factors will not affect the accuracy of such forward-looking statements. These risks include, but are not limited to, the ability to retain key personnel, the ability to continue investing in infrastructure to support growth, the ability to obtain financing on acceptable terms, the continued quality of our products, customer experience and retention, the development of third party government and non-government consumer sales channels, management's estimates of consumer demand in Canada and in jurisdictions where the Company exports, expectations of future results and expenses, the availability of additional capital to complete construction projects and facilities improvements, the risk of successful integration of acquired business and operations, management's estimation that SG&A will grow only in proportion to revenue growth, the ability to expand and maintain distribution capabilities, the impact of competition, the general impact of financial market conditions, the yield from cannabis growing operations, product demand, changes in prices of required commodities, competition, and the possibility for changes in laws, rules, and regulations in the industry, epidemics, pandemics or other public health crises, and other risks as set out under "Risk Factors" contained in the Annual Information Form dated June 10, 2026 (the "2026 AIF"). Readers are urged to consider the risks, uncertainties and assumptions carefully in evaluating the forward-looking statements. The Company cautions that the list of risks, uncertainties and other factors described in the 2026 AIF is not exhaustive and other factors could also adversely affect its results. Although the Company believes that the expectations conveyed by the forward-looking statements are reasonable based on the information available to the Company on the date hereof, no assurance can be given as to future results, approvals or achievements.
View original content to download multimedia:https://www.prnewswire.com/news-releases/aurora-a-global-leader-in-medical-cannabis-announces-results-of-2026-annual-general-meeting-302846555.html
SOURCE Aurora Cannabis Inc.